Freedom of information (FOI) releases from MHRA

This is a disclosure log of Medicines and Healthcare products Regulatory Agency's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters

  • Keywords filters

  • Year filters

  • Month filters

2,230 disclosures

  1. Inquiry regarding Public Assessment Reports for Ibuprofen 100mg/5mL Oral Suspension

    Could you please confirm whether PAR’s are available for these products? If any of these PARs is not available, could you please advise under which authorisation route the product was approved, and what the reference product is? • PL 00142/0977, for which Accord is the MA holder • PL 15513/0157, for which McNeil is the MA holder • PL 20416/0535, for which Crescent Pharma Limited is the MA holder • PL 46302/0011, for which Mylan is the MA holder • PL 16028/0034, for which Galpharm is the MA holder

    Published: 12 August 2026

  2. Ixazomib hard capsules (PLGB 15475/0059, PLGB 15475/0060 and PLGB 15475/0061)

    Please can you kindly provide the finished product manufacturer(s) name(s) and address(s) as well as the Active Substance Manufacturer(s) details for: Ixazomib 2.5 mg, 3 mg and 4 mg hard capsules (previously called Ninlaro hard capsules) MA numbers: PLGB 15475/0059, PLGB 15475/0060 and PLGB 15475/0061 MAH: Takeda Pharma A/S, Delta Park 45, 2665 Vallensbaek Strand, Denmark

    Published: 12 August 2026

  3. Enforcement data

    Please provide the following: • the number of times statutory powers were exercised to require the disclosure of documents or information in connection with enforcement action or enforcement investigations; • the number of times statutory powers were exercised to compel individuals to attend interviews in connection with enforcement action or enforcement investigations; and • the number of inspections of physical premises undertaken in connection with enforcement action or enforcement investigations.

    Published: 12 August 2026

  4. List of Inspections since April 2025 (CSV)

    See attached

    Published: 12 August 2026

  5. FOI - Regulation 16A(3) Patient Communication - GPhC

    Dear MHRA Freedom of Information Team, This request is made under the Freedom of Information Act 2000. It is submitted as part of an ongoing, transparent research programme examining the regulatory, criminal-law, equality, and real-world impacts of the framework governing cannabis-based products for medicinal use (CBPMs). The programme builds on material previously submitted to the Advisory Council on the Misuse of Drugs (ACMD) Call for Evidence on CBPMs, which closed on 17 October 2025, and on subsequent analytical updates and correspondence provided to the ACMD as the evidence base has continued to develop. Background Attached are Department of Health and Social Care responses FOI-1683941 and FOI-1688183. In those responses DHSC states, amongst other things, that: • responsibility for informing patients how to take prescribed medicines rests with prescribers and dispensing pharmacies; • product labels and clinics would be expected to communicate information concerning the correct route of administration; • healthcare regulators are responsible for ensuring healthcare professionals meet professional standards; and • DHSC would expect communication to specify in clear terms that smoking prescribed cannabis-based products for medicinal use is illegal and therefore a criminal offence. Also attached is a Patient Communication Evidence Pack containing representative examples of patient-facing packaging and dispensing labels supplied with prescribed cannabis-based products for medicinal use. The examples demonstrate communication of matters including: • route of administration; • vaporisation instructions; • smoking warnings; • storage requirements; • controlled-drug status; and • driving-related warnings. FOI_1D1b - MHRA 19/06/2026 This request concerns recorded information relating to communication to patients of the legal consequences arising from Regulation 16A(3) of the Misuse of Drugs Regulations 2001. For clarity: • this request concerns formally recorded information only; • it does not seek draft material; • it does not seek informal communications; • it does not seek legal advice; • it does not seek opinions regarding the merits of the policy. Requested Information 1. Has MHRA considered whether patient-facing information relating to prescribed cannabis-based products for medicinal use should communicate the legal consequences arising from Regulation 16A(3) of the Misuse of Drugs Regulations 2001? 2. If the answer to Question 1 is yes, please provide the records documenting that consideration. 3. If the answer to Question 1 is no, please identify any organisation, authority or office-holder regarded as responsible for considering that issue. 4. If MHRA has not considered the issue itself, does MHRA hold any recorded information identifying any requirement, expectation or mechanism through which communication of those legal consequences should occur?

    Published: 12 August 2026

  6. MHRA Yellow Card Contact Us Form Submission

    Hello, I would like to request data on all reported side effects in the UK in relation to 6 in 1 vaccines.

    Published: 12 August 2026

  7. FOI Request: GMP Inspection Reports for Aptuit (Oxford) Limited (Feb 2026)

    Pursuant to the Freedom of Information Act 2000, I am writing to formally request copies of the final Good Manufacturing Practice (GMP) Inspection Reports (and any associated final compliance/closure notifications) for the inspections concluded on 24 February 2026 at the following facilities: 1. Site Name: Aptuit (Oxford) Limited * Address: Abingdon, OX14 4SD, United Kingdom * Inspection End Date: 24 February 2026 1. Site Name: Aptuit (Oxford) Limited * Address: Abingdon, OX14 4SA, United Kingdom * Inspection End Date: 24 February 2026

    Published: 12 August 2026

  8. I am requesting information about peptide seizures by MHRA

    Please provide me with the following information under the FOIA: 1) How many peptide products were seized by the MHRA during in 2024 and 2025? Please break this down by type of peptide (e.g. Retatrutide). 2) How many peptide products were seized by the MHRA in the first 5 months of 2026? Please break this down by type of peptide.

    Published: 12 August 2026

  9. To provide the public assessment report for Phosphate Sandoz

    Please can you kindly provide the public assessment report for Phosphate Sandoz PL 44490/0002 or if unable to locate a public one, please can MHRA kindly provide any aspects of the assessment report which indicate which literature references were used as the basis for approval.

    Published: 12 August 2026

  10. Alkacit 1080 mg MR tablets (PL 59076/0001) - published litterature/product link

    The undersigned hereby requests access to the registration documentation for Alkacit 1080 mg modified-release tablets (PL 59076/0001). The request is currently limited to information regarding whether/how the applicant has established a link between the published literature and the applied-for medicinal product (pharmaceutical form, excipients, etc.).

    Published: 12 August 2026